VCAM1 and metabolic dysfunction-associated steatohepatitis: Previous studies investigating the integrin ligand VCAM-1 focused on the hepatic endothelium [20,21], while only a few studies have mentioned the expression of VCAM-1 in HSCs, without providing any mechanistic evidence on its possible role in HSC function and HSC-related pathophysiology during NAFLD and NASH [14,15].